Diagnosing Single and Multiple Drug Hypersensitivity in Children: A Tertiary Care Center Retrospective Study
- PMID: 36553397
- PMCID: PMC9776612
- DOI: 10.3390/children9121954
Diagnosing Single and Multiple Drug Hypersensitivity in Children: A Tertiary Care Center Retrospective Study
Abstract
Drug hypersensitivity reactions (DHRs) are a type of adverse drug reactions with heterogeneous pathophysiological mechanisms and a broad spectrum of clinical manifestations. Since over-diagnosing is common in children, a complete allergy work-up is needed. A cross-sectional study was conducted at a tertiary care institution, covering the five-year period. Five hundred and four patients of both sexes, mean age 7.5 and with a medical history suggestive of DHR were evaluated. ENDA/EAACI guidelines were used for a diagnostic algorithm. Single drug hypersensitivity was registered in 375 patients and multiple drug hypersensitivity in 129. The main culprits in medical history were antibiotics (83%), non-steroidal anti-inflammatory drugs (NSAIDs) (8.4%) and analgoantipyretics (3.8%). Skin involvement was registered in 96.2%. DHRs were confirmed in 4.4% patients-six patients had positive skin tests and 13 had a positive drug provocation test. In the proven DHRs group, the main agents were antibiotics (72.7%), followed by NSAIDs (8.3%), and of all the skin manifestations, urticaria was most common (78.2%), followed by exanthema (10.5%) and angioedema (5.3%). Considering the above, anticipating DHRs and a proper referral of children to an allergologist is a key step in the assessment of drug hypersensitivity. A complete allergy work-up prevents unnecessary drug exclusion and allows most children to safely continue the use of first-line medications when needed.
Keywords: allergy diagnostic algorithm; antibiotics; children; cutaneous manifestations; multiple drug hypersensitivity.
Conflict of interest statement
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Davor Plavec reports grants, personal fees from GlaxoSmithKline; personal fees, non-financial support from Menarini, Philips, and Revenio; personal fees from Pliva, Boehringer Ingelheim, Belupo, Novartis, MSD, and Chiesi, not related to the submitted paper. Asist. Zoran Lekovic reports personal fees from AbbVie, Kibid and New Med, not related to the submitted paper. Aleksa Lekovic and Zoran Lekovic are close relatives. The authors report no other conflicts of interest.
Figures


Similar articles
-
Epidemiology and drug allergy results in children investigated in allergy unit of a tertiary-care paediatric hospital setting.Ital J Pediatr. 2020 Jan 10;46(1):5. doi: 10.1186/s13052-019-0753-4. Ital J Pediatr. 2020. PMID: 31924232 Free PMC article.
-
Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs in adults: Beyond current classification.Allergol Immunopathol (Madr). 2023 Sep 1;51(5):84-92. doi: 10.15586/aei.v51i5.946. eCollection 2023. Allergol Immunopathol (Madr). 2023. PMID: 37695234
-
Is a Drug Allergy in a Patient's History Real? Our Experience with Diagnostic Drug Provocation Tests.Medicina (Kaunas). 2025 Feb 23;61(3):386. doi: 10.3390/medicina61030386. Medicina (Kaunas). 2025. PMID: 40142197 Free PMC article.
-
An EAACI task force report: recognising the potential of the primary care physician in the diagnosis and management of drug hypersensitivity.Clin Transl Allergy. 2018 May 10;8:16. doi: 10.1186/s13601-018-0202-2. eCollection 2018. Clin Transl Allergy. 2018. PMID: 29760877 Free PMC article. Review.
-
The controversy of drug hypersensitivity in patients with cystic fibrosis and review of the literature.Pediatr Allergy Immunol. 2022 Feb;33(2):e13719. doi: 10.1111/pai.13719. Pediatr Allergy Immunol. 2022. PMID: 34907613 Review.
Cited by
-
Recent findings on drug hypersensitivity in children.Front Allergy. 2024 Feb 7;5:1330517. doi: 10.3389/falgy.2024.1330517. eCollection 2024. Front Allergy. 2024. PMID: 38384771 Free PMC article. Review.
-
Practical Approach to Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Children.Pharmaceuticals (Basel). 2023 Sep 1;16(9):1237. doi: 10.3390/ph16091237. Pharmaceuticals (Basel). 2023. PMID: 37765044 Free PMC article.
-
Outcomes of drug provocation tests in children with chronic complications and comorbidities: Case series.J Allergy Clin Immunol Glob. 2025 Feb 3;4(2):100436. doi: 10.1016/j.jacig.2025.100436. eCollection 2025 May. J Allergy Clin Immunol Glob. 2025. PMID: 40091883 Free PMC article.
References
-
- Gomes E.R., Brockow K., Kuyucu S., Saretta F., Mori F., Blancalopez N., Ott H., Atanaskovicmarkovic M., Kidon M.I., Caubet J.-C.R.J.-P., et al. Drug hypersensitivity in children: Report from the pediatric task force of the EAACI Drug Allergy Interest Group. Allergy: European J. Allergy Clin. Immunol. 2016;71:149–161. doi: 10.1111/all.12774. - DOI - PubMed
LinkOut - more resources
Full Text Sources